Academia Sinica, a research institution based in Taiwan, has signed a memorandum of understanding (MOU) to collaborate with the Lilly TB Drug Discovery Initiative on target-based screening for the discovery of new tuberculosis (TB) drugs.

The Lilly TB Drug Discovery Initiative is a not-for-profit public-private partnership designed to accelerate early-stage drug discovery for new TB treatments by bringing together specialists from around the world and opening access to large, private molecular libraries.

Academia Sinica president Chi-Huey Wong said that he hoped to make contributions in the areas related to genome sequencing and high-throughput drug discovery.

Lilly’s vice-president of scientific affairs Gail Cassell said that to have Dr Chi-Huey Wongon on the Steering Committee will provide invaluable guidance to the company’s efforts.

Under the MOU, Academia Sinica will join Eli Lilly and Company and the US Infectious Disease Research Institute, as well as the US National Institute of Allergy and Infectious Diseases.

The Lilly TB Drug Discovery Initiative also includes representatives of government agencies, philanthropic organisations, pharmaceutical companies, universities and other research institutions.